SHANDONG Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHANDONG
SHANDONG has sixteen approved drugs.
There are five US patents protecting SHANDONG drugs. There are two tentative approvals on SHANDONG drugs.
There are twenty-nine patent family members on SHANDONG drugs in fourteen countries and fifty-four supplementary protection certificates in thirteen countries.
Summary for SHANDONG
| International Patents: | 29 |
| US Patents: | 5 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 16 |
Drugs and US Patents for SHANDONG
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-001 | Jan 13, 2023 | DISCN | Yes | No | 10,098,882 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-002 | Jan 13, 2023 | RX | Yes | Yes | 10,406,161 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Shandong Xinhua | IBUPROFEN | ibuprofen | TABLET;ORAL | 202413-002 | Nov 23, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shandong Luye | RYKINDO | risperidone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212849-004 | Jan 13, 2023 | RX | Yes | No | 10,406,161 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SHANDONG Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2586306 | ⤷ Start Trial |
| Hungary | E046004 | ⤷ Start Trial |
| Hong Kong | 1185560 | ⤷ Start Trial |
| Japan | 2015143259 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for SHANDONG Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0759917 | 38/2002 | Austria | ⤷ Start Trial | PRODUCT NAME: OSELTAMIVIR PHOSPHAT; REGISTRATION NO/DATE: EU/1/02/222/001 EU/1/02/222/002 20020620 |
| 0521471 | 0391023-9 | Sweden | ⤷ Start Trial | PRODUCT NAME: ROSUVASTATIN |
| 2101777 | 201640021 | Slovenia | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN IN COMBINATION WITH TADALAFIL; NATIONAL AUTHORISATION NUMBER: EU/1/08/451/001-004; DATE OF NATIONAL AUTHORISATION: 20151120; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 2101777 | 2016C/032 | Belgium | ⤷ Start Trial | PRODUCT NAME: AMBRISENTAN EN COMBINAISON AVEC LE TADALAFIL; AUTHORISATION NUMBER AND DATE: EU/1/08/451 20151125 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
